Profilaxis de la infección por citomegalovirus en el trasplante renal [artículo]
Por: Aguado García, José María [Enfermedades Infecciosas]
.
Colaborador(es): Servicio de Medicina Interna.
Editor: Enfermedades Infecciosas y Microbiología Clínica, 2011Descripción: 29(Suppl 6):38-41.Recursos en línea: Solicitar documento Resumen:
| Tipo de ítem | Ubicación actual | Signatura | Estado | Fecha de vencimiento |
|---|---|---|---|---|
Artículo
|
PC4986 (Navegar estantería) | Disponible |
Formato Vancouver:
Aguado JM, Gil Vernet S. Profilaxis de la infección por citomegalovirus en el trasplante renal. Enferm Infecc Microbiol Clin. 2011;29 Suppl 6:38-41.
PMID: 22541921
Contiene 25 referencias.
Cytomegalovirus (CMV) infection remains a major problem in renal transplant recipients. CMV produces not only febrile syndromes and/or visceral disease but also contributes to the development of acute rejection and chronic graft failure. Valganciclovir prophylaxis has represented a major advance in controlling this infection, but late CMV infection after prophylaxis can occur, especially when universal prophylaxis is used. The use of valganciclovir prophylaxis for 200 days is more effective than prophylaxis for 100 days but does not completely prevent this problem. Prophylaxis based on the detection of CMV viremia (early prophylaxis or preemptive therapy) may prevent the development of delayed CMV disease, but has the disadvantage of requiring more intensive monitoring of viremia and does not prevent the development of viremia and its potential consequences in the long term. This article reviews current recommendations for prophylaxis of CMV disease in renal transplantation.
No hay comentarios para este ejemplar.